Item 2.02. Results of Operations and Financial Condition.

On May 7, 2020, Progenics Pharmaceuticals, Inc. ("Progenics") issued a press release announcing its financial results and business update for the first quarter of 2020. A copy of the foregoing press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 2.02 by reference.




Item 7.01.       Regulation FD Disclosure.

Pursuant to Regulation FD, Progenics is furnishing as Exhibit 99.1 its financial results and business update for the first quarter of 2020.

The information contained in Items 2.02 and 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 9.01       Financial Statements and Exhibits



(d)     Exhibits.



Exhibit
  No.      Description

 99.1        Press Release announcing Progenics' first quarter of 2020 financial
           results and business update, dated May 7, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses